Study of a clot-busting drug before thrombectomy for stroke
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests giving a clot-dissolving medicine (rhPro-UK) through a vein before a procedure to remove a large blood clot in the brain. It is for people who had a stroke 4.5 to 24 hours ago and are already scheduled for clot removal. The goal is to see if the medicine helps improve blood flow and outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years of age or older.
- You had a sudden loss of brain function (stroke) from a blocked artery, and it has been between 4.5 and 24 hours since you were last seen well.
- Before this stroke, you were able to live independently (no major disability).
- Your stroke symptoms are severe, with a score of 6 or higher on a standard stroke scale.
- Brain imaging shows a large artery blockage in a specific location and signs that some brain tissue can still be saved.
- You are already scheduled to have a procedure (thrombectomy) to remove the clot.
- You or your legal representative can sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a clot-dissolving medication directly into the brain's blood vessels during a standard procedure (mechanical thrombectomy) can improve outcomes for people with a stroke caused by a blockage in a medium-sized artery. It may be an option for patients who arrive at the hospital within 24 hours of symptom onset and have enough salvageable brain tissue.
This trial tests a medicine given through a vein to break up blood clots in medium-sized brain arteries. It may help people who had a stroke between 4.5 and 24 hours ago and cannot have the standard clot-removal procedure.
This trial tests if removing a large blood clot from the brain up to 3 days after a stroke improves recovery compared to standard medical care alone. It is for patients who have a severe stroke and are otherwise healthy enough for the procedure.
This trial tests a clot-dissolving medication (pro-urokinase) for people with recent strokes in the back of the brain. You would be treated 4.5 to 9 hours after symptoms start, which is beyond the typical treatment window, using special MRI patterns to identify patients most likely to benefit.
This trial compares two clot-dissolving medications (tenecteplase and reteplase) given before a procedure to remove a large clot from a brain artery. It aims to see which drug works better for people who have had an acute ischemic stroke and are eligible for both treatments.
This trial tests a new clot-busting medicine called tenecteplase, given directly into the blood vessel in the brain, to treat strokes caused by a blockage in a medium-sized artery. The goal is to see if it can help restore blood flow and reduce disability, especially for patients who can be treated within 24 hours of stroke onset.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.